Reported Earlier, HUTCHMED To Present Sovleplenib Phase III ESLIM-01 Study And Hematological Malignancy Programs Data At The Upcoming EHA2024 Congress

5/17/24 1:25:44 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $HCM alert in real time by email

HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces that topline and subgroup results from the ESLIM-01 Phase III study of sovleplenib, as well as new and updated data related to novel investigational hematological malignancy therapies HMPL-306, HMPL-760 and tazemetostat, will be presented at the upcoming European Hematology Association ("EHA") Hybrid Congress, taking place on June 13-16, 2024 in Madrid, Spain and online.

Get the next $HCM alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$HCM

Date	Price Target	Rating	Analyst
11/24/2023		Hold → Buy	Deutsche Bank
5/4/2022		Buy → Hold	Deutsche Bank
9/22/2021	$46.00	Buy → Neutral	Goldman
8/3/2021	$52.00	Buy	Jefferies

More analyst ratings

$HCM
Press Releases

Fastest customizable press release news feed in the world

HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan
— Launch follows approval by Japanese Ministry of Health, Labour and Welfare in September 2024 — — Milestone payment to be made to HUTCHMED from Takeda — — Fruquintinib already launched in several regions including the United States, Europe and China — HONG KONG, SHANGHAI & FLORHAM PARK, N.J., Nov. 21, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces that it will receive a milestone payment following the pricing approval and launch of FRUZAQLA® (fruquintinib) 1mg/5mg capsules in Japan by its partner Takeda (NYSE:TAK) for patients with previously treated metastatic colorectal cancer ("CRC"). This follows approval for the manuf
11/21/24 11:30:00 PM ET
$HCM
$TAK
Biotechnology: Pharmaceutical Preparations
Health Care
HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 20, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM:HCM, HKEX:13) today announces that Dr Chaohong Hu (Dr Mary Hu) is appointed as an Independent Non-executive Director and a member of the Technical Committee of the Company with effect from November 21, 2024. Dr Hu has over 20 years of experience in the development of therapeutic antibodies, antibody-drug conjugates, and vaccines. Throughout her career, she has demonstrated strong leadership and innovative capabilities, leading various research and development initiatives. Dr Hu's expertise spans from early-stage discovery to clinical developme
11/20/24 4:30:00 AM ET
$HCM
Biotechnology: Pharmaceutical Preparations
Health Care
HUTCHMED Highlights Clinical Data to be Presented at the 2024 ASH Annual Meeting and the 2024 ESMO Asia Congress
HONG KONG, SHANGHAI, and FLORHAM PARK, N.J., Nov. 05, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from the sovleplenib ESLIM-01 Phase III trial, as well as several investigator-initiated studies of compounds discovered by HUTCHMED will be presented at the American Society of Hematology ("ASH") Annual Meeting taking place on December 7-10, 2024 in San Diego, USA, and the European Society for Medical Oncology ("ESMO") Asia Congress 2024, taking place on December 6-8, 2024 in Singapore. Long-term safety and efficacy data from a follow-on, open-label sub-study of the extension stage of ESLIM-01 Phase III st
11/5/24 11:00:00 PM ET
$HCM
Biotechnology: Pharmaceutical Preparations
Health Care

$HCM
Leadership Updates

Live Leadership Updates

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 20, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM:HCM, HKEX:13) today announces that Dr Chaohong Hu (Dr Mary Hu) is appointed as an Independent Non-executive Director and a member of the Technical Committee of the Company with effect from November 21, 2024. Dr Hu has over 20 years of experience in the development of therapeutic antibodies, antibody-drug conjugates, and vaccines. Throughout her career, she has demonstrated strong leadership and innovative capabilities, leading various research and development initiatives. Dr Hu's expertise spans from early-stage discovery to clinical developme
11/20/24 4:30:00 AM ET
$HCM
Biotechnology: Pharmaceutical Preparations
Health Care
HUTCHMED announces retirement of Chairman, appointment of new Chairman and change of members of board committees
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., May 17, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM:HCM, HKEX:13) today announces:- (a) the retirement of Mr Simon To from the position as Chairman and Executive Director, after 23 years with the Company; and (b) the appointment of Dr Dan Eldar as the new Chairman. Dr Eldar has been a Non-executive Director of the Company since 2016. He has more than 30 years of experience as a senior executive, leading global operations in biotechnology, healthcare, telecommunications and water. He is an executive director of Hutchison Water Israel E.P.C Ltd, an associate of CK Hutchison group, which
5/17/24 10:00:00 AM ET
$HCM
Biotechnology: Pharmaceutical Preparations
Health Care
HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee
HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM: HCM, HKEX: 13) today announces that Dr Renu Bhatia is appointed as an Independent Non-executive Director and a member of Technical Committee of the Company with effect from May 13, 2024. Dr Bhatia, a licensed physician, has over 25 years of experience in the healthcare, finance and fintech, and regulatory sectors. She is an experienced board director and chair, with a healthcare and financial services background in investment banking, asset management, venture capital and compliance. The Board of HUTCHMED is of the vie
5/8/24 4:30:00 AM ET
$HCM
Biotechnology: Pharmaceutical Preparations
Health Care

$HCM
Financials

Live finance-specific insights

HUTCHMED to Announce 2024 Half-Year Financial Results
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 26, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; SEHK:13) will be announcing its interim results for the six months ended June 30, 2024 on Wednesday, July 31, 2024 at 7:00 am Eastern Daylight Time (EDT) / 12:00 noon British Summer Time (BST) / 7:00 pm Hong Kong Time (HKT). Analysts and investors are invited to join a conference call and audio webcast presentation with Q&A, conducted by HUTCHMED management. The English conference call and audio webcast will be held on Wednesday, July 31, 2024, at 8:00 am EDT (1:00 pm BST / 8:00 pm HKT). The Chinese (Putonghua) webcast will be held at 8:30 am HKT /
6/26/24 4:30:00 AM ET
$HCM
Biotechnology: Pharmaceutical Preparations
Health Care
HUTCHMED to Announce 2023 Final Results
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 01, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year ended December 31, 2023 on Wednesday, February 28, 2024 at 6:30 am Eastern Standard Time (EST) / 11:30 am Greenwich Mean Time (GMT) / 7:30 pm Hong Kong Time (HKT). Analysts and investors are invited to join a conference call and audio webcast presentation with Q&A, conducted by HUTCHMED management. The English conference call and audio webcast will take place at 7:30 am EST / 12:30 pm GMT / 8:30 pm HKT on Wednesday, February 28, 2024. In addition to the usual English webcast, there wi
2/1/24 3:30:00 AM ET
$HCM
Biotechnology: Pharmaceutical Preparations
Health Care
HUTCHMED Reports 2023 Interim Results and Provides Business Updates
Strong execution on strategic direction, delivering near-term value while charting a path for growth, exemplified by global partnership with Takeda Revenue grew 164% (173% CER) to US$533 million, with net income to HUTCHMED of US$169 million (which include US$259 million of the upfront recognized from Takeda) Company to Host Interim Results Call & Webcast Today at 8 p.m. HKT / 1 p.m. BST / 8 a.m. EDT Company to host a Capital Markets Day in Q4 this year HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., July 31, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED", the "Company" or "we") (Nasdaq/AIM:HCM; HKEX:13), the innovative, commercial-stage biopharmaceutical com
7/31/23 7:41:53 AM ET
$HCM
Biotechnology: Pharmaceutical Preparations
Health Care

Reported Earlier, HUTCHMED To Present Sovleplenib Phase III ESLIM-01 Study And Hematological Malignancy Programs Data At The Upcoming EHA2024 Congress

Chat with this insight

Recent Analyst Ratings for
$HCM

$HCM
Press Releases

Fastest customizable press release news feed in the world

HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

HUTCHMED Highlights Clinical Data to be Presented at the 2024 ASH Annual Meeting and the 2024 ESMO Asia Congress

$HCM
Market Insights

Live Market Insights

Why HUTCHMED Stock Is Moving Higher Friday

HUTCHMED shares are trading higher after the company announced that its NDA for Tazemetostat for the treatment of relapsed or refractory follicular lymphoma was accepted in China with Priority Review status.

Reported Late Wednesday, HUTCHMED's Tazemetostat For Relapsed/Refractory Follicular Lymphoma Secures NDA Acceptance And Priority Review In China

$HCM
Leadership Updates

Live Leadership Updates

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

HUTCHMED announces retirement of Chairman, appointment of new Chairman and change of members of board committees

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

$HCM
SEC Filings

$HCM
Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form 6-K filed by HUTCHMED (China) Limited

SEC Form 6-K filed by HUTCHMED (China) Limited

SEC Form 6-K filed by HUTCHMED (China) Limited

SEC Form SC 13G/A filed by HUTCHMED (China) Limited (Amendment)

SEC Form SC 13G/A filed by HUTCHMED (China) Limited (Amendment)

SEC Form SC 13D/A filed by HUTCHMED (China) Limited (Amendment)

$HCM
Financials

Live finance-specific insights

HUTCHMED to Announce 2024 Half-Year Financial Results

HUTCHMED to Announce 2023 Final Results

HUTCHMED Reports 2023 Interim Results and Provides Business Updates

$HCM
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

HUTCHMED upgraded by Deutsche Bank

HUTCHMED downgraded by Deutsche Bank

HUTCHMED downgraded by Goldman with a new price target

Reported Earlier, HUTCHMED To Present Sovleplenib Phase III ESLIM-01 Study And Hematological Malignancy Programs Data At The Upcoming EHA2024 Congress

Chat with this insight

Recent Analyst Ratings for $HCM

$HCM Press Releases

Fastest customizable press release news feed in the world

HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

HUTCHMED Highlights Clinical Data to be Presented at the 2024 ASH Annual Meeting and the 2024 ESMO Asia Congress

$HCM Market Insights

Live Market Insights

Why HUTCHMED Stock Is Moving Higher Friday

HUTCHMED shares are trading higher after the company announced that its NDA for Tazemetostat for the treatment of relapsed or refractory follicular lymphoma was accepted in China with Priority Review status.

Reported Late Wednesday, HUTCHMED's Tazemetostat For Relapsed/Refractory Follicular Lymphoma Secures NDA Acceptance And Priority Review In China

$HCM Leadership Updates

Live Leadership Updates

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

HUTCHMED announces retirement of Chairman, appointment of new Chairman and change of members of board committees

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

$HCM SEC Filings

$HCM Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form 6-K filed by HUTCHMED (China) Limited

SEC Form 6-K filed by HUTCHMED (China) Limited

SEC Form 6-K filed by HUTCHMED (China) Limited

SEC Form SC 13G/A filed by HUTCHMED (China) Limited (Amendment)

SEC Form SC 13G/A filed by HUTCHMED (China) Limited (Amendment)

SEC Form SC 13D/A filed by HUTCHMED (China) Limited (Amendment)

$HCM Financials

Live finance-specific insights

HUTCHMED to Announce 2024 Half-Year Financial Results

HUTCHMED to Announce 2023 Final Results

HUTCHMED Reports 2023 Interim Results and Provides Business Updates

$HCM Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

HUTCHMED upgraded by Deutsche Bank

HUTCHMED downgraded by Deutsche Bank

HUTCHMED downgraded by Goldman with a new price target

Recent Analyst Ratings for
$HCM

$HCM
Press Releases

$HCM
Market Insights

$HCM
Leadership Updates

$HCM
SEC Filings

$HCM
Large Ownership Changes

$HCM
Financials

$HCM
Analyst Ratings